Division of Uro-Oncology, Max Institute of Cancer Care, Saket, New Delhi, India.
Division of Uro-Oncology and Robotic Surgery, Apollo Hospitals, Mumbai, India.
J Robot Surg. 2022 Oct;16(5):1091-1097. doi: 10.1007/s11701-021-01339-9. Epub 2021 Nov 28.
Robot-assisted radical prostatectomy (RARP) is challenging in men with prior history of transurethral resection of the prostate (TURP). Few studies analyze this peculiar group of patients, and hence we sought to investigate the outcome of RARP in post-TURP men. We interrogated our prospectively maintained database containing 643 patients who underwent RARP from January 2012 to December 2020. We matched 36 men with prior history of TURP consecutively to 72 men without prior TURP. The groups were matched for age, body mass index (BMI), Charlson comorbidity index (CCI), serum PSA, International Society of Urological Pathology (ISUP) grade groups and clinical stage. Men with prior history of stricture surgeries, pelvic radiation, ablative laser procedures, Urolift and Rezum were excluded from the study. Fisher's Exact test/Chi-square was used for the comparison of categorical variables. Mann-Whitney test (Independent group/Unpaired data) and Wilcoxon sign rank test (for paired data) were employed to analyze continuous variables. The complication rates, median day of drain removal and length of hospital stay were similar between the groups. The TURP group required bladder neck reconstruction twice as often as the non-TURP group (58.3% versus 29.1%, p = 0.0035) and a longer duration of postoperative catheterization (10 versus 8 days, p = 0.0005). The rate of positive surgical margins was higher in the TURP group (30.5% versus 25%, p = 0.5414), albeit statistically insignificant. Biochemical recurrence (BCR) at one year (48.8% versus 60%, p = 0.0644) and zero pad/one safety-pad continence rates at one, three, six and twelve months were also not significantly different (14.3%, 35.4%, 59.2%, 81.6% for non TURP group versus 9.1%, 28.6%, 53.6%, 76.0% for TURP group). On multivariate analysis, prior TURP was not associated with a higher risk of BCR, margin positivity or incontinence. The oncological and functional outcomes of RARP post-TURP are comparable to men without prior TURP.
机器人辅助根治性前列腺切除术 (RARP) 在既往经尿道前列腺切除术 (TURP) 病史的男性中具有挑战性。很少有研究分析这组特殊的患者,因此我们试图研究 RARP 在 TURP 后男性中的结果。我们查询了我们从 2012 年 1 月至 2020 年 12 月期间前瞻性维护的包含 643 例接受 RARP 的患者数据库。我们连续匹配了 36 例有既往 TURP 病史的男性和 72 例无 TURP 病史的男性。两组在年龄、体重指数 (BMI)、Charlson 合并症指数 (CCI)、血清 PSA、国际泌尿病理学会 (ISUP) 分级组和临床分期方面进行了匹配。既往有狭窄手术、盆腔放疗、消融激光手术、Urolift 和 Rezum 的患者被排除在研究之外。Fisher 确切检验/卡方检验用于比较分类变量。Mann-Whitney 检验(独立组/非配对数据)和 Wilcoxon 符号秩检验(配对数据)用于分析连续变量。两组的并发症发生率、中位引流管拔除天数和住院时间相似。TURP 组需要膀胱颈重建的次数是无 TURP 组的两倍(58.3%比 29.1%,p=0.0035),术后导尿管留置时间也更长(10 天比 8 天,p=0.0005)。TURP 组的阳性切缘率更高(30.5%比 25%,p=0.5414),但无统计学意义。TURP 组的生化复发率(BCR)在 1 年时(48.8%比 60%,p=0.0644)和 1、3、6 和 12 个月时零垫/一安全垫控尿率也无显著差异(无 TURP 组分别为 14.3%、35.4%、59.2%、81.6%,TURP 组分别为 9.1%、28.6%、53.6%、76.0%)。多变量分析显示,既往 TURP 与 BCR、切缘阳性或尿失禁的风险增加无关。TURP 后 RARP 的肿瘤学和功能结果与无 TURP 病史的男性相当。